Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3α and MSP-9 in individuals from Brazilian endemic area

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lima Junior, Josué C ^a   Rodrigues da Silva, Rodrigo N ^a   Banic, Dalma M ^a   Jiang, Jianlin ^b   Singh, Balwan ^b   Fabrício Silva, Gustavo M ^c   Porto, Luís C S ^c   Meyer, Esmeralda V S ^a,b   Moreno, Alberto ^b,e   Rodrigues, Maurício M ^d   Barnwell, John W ^f   Galinski, Mary R ^b,e   de Oliveira Ferreira, Joseli ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b EMORY UNIVERSITY   (United States)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G; INSECT PROTEIN; PROTEIN MSP 1; PROTEIN MSP 3ALPAHA; PROTEIN MSP 9; UNCLASSIFIED DRUG; HLA DQ ANTIGEN; HLA-DQB1 ANTIGEN; MEMBRANE PROTEIN; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3, PLASMODIUM; MEROZOITE SURFACE PROTEIN 9, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRAZIL; CARBOXY TERMINAL SEQUENCE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENDEMIC DISEASE; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALARIA; MALE; PLASMODIUM VIVAX; PROTEIN BLOOD LEVEL; CHILD; ETHNIC GROUP; GENETICS; IMMUNOLOGY; INTERVIEW; MIDDLE AGED; PLASMODIUM VIVAX MALARIA; PREVALENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, PROTOZOAN; BRAZIL; CHILD; ETHNIC GROUPS; GENE FREQUENCY; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; IMMUNOGLOBULIN G; INTERVIEWS AS TOPIC; MALARIA, VIVAX; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; PREVALENCE; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS;

EID: 84861398052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036419     Document Type: Article

References (59)

1. WHO, (2005) World Malaria Report.
2. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, et al. (2009) Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9: 555-566.
3. Higgs ES, Sina B, (2005) Plasmodium vivax vaccine research: steps in the right direction. Am J Trop Med Hyg 73: 1-2.
4. Suh KN, Kain KC, Keystone JS, (2004) Malaria. CMAJ 170: 1693-1702.
5. Miller LH, Baruch DI, Marsh K, Doumbo OK, (2002) The pathogenic basis of malaria. Nature 415: 673-679.
6. Chauhan VS, Yazdani SS, Gaur D, (2010) Malaria vaccine development based on merozoite surface proteins of Plasmodium falciparum. Hum Vaccin 6.
7. Iyer J, Gruner AC, Renia L, Snounou G, Preiser PR, (2007) Invasion of host cells by malaria parasites: a tale of two protein families. Mol Microbiol 65: 231-249.
8. Galinski MR, Barnwell JW, (2008) Plasmodium vivax: who cares? Malar J 7 (Suppl 1): S9.
9. Herrera S, Corradin G, Arevalo-Herrera M, (2007) An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 23: 122-128.
10. del Portillo HA, Longacre S, Khouri E, David PH, (1991) Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc Natl Acad Sci U S A 88: 4030-4034.
11. Galinski MR, Corredor-Medina C, Povoa M, Crosby J, Ingravallo P, et al. (1999) Plasmodium vivax merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich central domain. Mol Biochem Parasitol 101: 131-147.
12. Galinski MR, Ingravallo P, Corredor-Medina C, Al-Khedery B, Povoa M, et al. (2001) Plasmodium vivax merozoite surface proteins-3beta and-3gamma share structural similarities with P. vivax merozoite surface protein-3alpha and define a new gene family. Mol Biochem Parasitol 115: 41-53.
13. Barnwell JW, Galinski MR, DeSimone SG, Perler F, Ingravallo P, (1999) Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites. Exp Parasitol 91: 238-249.
14. Vargas-Serrato E, Barnwell JW, Ingravallo P, Perler FB, Galinski MR, (2002) Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum. Mol Biochem Parasitol 120: 41-52.
15. Lima-Junior JC, Jiang J, Rodrigues-da-Silva RN, Banic DM, Tran TM, et al. (2011) B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax Merozoite Surface Protein-3alpha (PvMSP-3alpha) in malaria exposed individuals from Brazilian Amazon. Vaccine.
16. Lima-Junior JC, Tran TM, Meyer EV, Singh B, De-Simone SG, et al. (2008) Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine 26: 6645-6654.
17. Soares IS, da Cunha MG, Silva MN, Souza JM, Del Portillo HA, et al. (1999) Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1. Am J Trop Med Hyg 60: 357-363.
18. Soares IS, Levitus G, Souza JM, Del Portillo HA, Rodrigues MM, (1997) Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun 65: 1606-1614.
19. Soares IS, Rodrigues MM, (2002) Immunogenic properties of the Plasmodium vivax vaccine candidate MSP1(19) expressed as a secreted non-glycosylated polypeptide from Pichia pastoris. Parasitology 124: 237-246.
20. de Oliveira CI, Wunderlich G, Levitus G, Soares IS, Rodrigues MM, et al. (1999) Antigenic properties of the merozoite surface protein 1 gene of Plasmodium vivax. Vaccine 17: 2959-2968.
21. Oliveira-Ferreira J, Vargas-Serrato E, Barnwell JW, Moreno A, Galinski MR, (2004) Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli. Vaccine 22: 2023-2030.
22. Yang C, Collins WE, Sullivan JS, Kaslow DC, Xiao L, et al. (1999) Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant. Infect Immun 67: 342-349.
23. Modiano D, Petrarca V, Sirima BS, Luoni G, Nebie I, et al. (1999) Different response to Plasmodium falciparum in west African sympatric ethnic groups: possible implications for malaria control strategies. Parassitologia 41: 193-197.
24. Modiano D, Chiucchiuini A, Petrarca V, Sirima BS, Luoni G, et al. (1999) Interethnic differences in the humoral response to non-repetitive regions of the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg 61: 663-667.
25. Germain RN, Stefanova I, (1999) The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 17: 467-522.
26. van Lith M, McEwen-Smith RM, Benham AM, (2010) HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM. J Biol Chem 285: 40800-40808.
27. Stern LJ, Calvo-Calle JM, (2009) HLA-DR: molecular insights and vaccine design. Curr Pharm Des 15: 3249-3261.
28. Davenport MP, Hill AV, (1996) Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Mol Med Today 2: 38-45.
29. Sinigaglia F, Guttinger M, Romagnoli P, Takacs B, (1990) Malaria antigens and MHC restriction. Immunol Lett 25: 265-270.
30. Johnson AH, Leke RG, Mendell NR, Shon D, Suh YJ, et al. (2004) Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1. Infect Immun 72: 2762-2771.
31. Johnson A, Leke R, Harun L, Ginsberg C, Ngogang J, et al. (2000) Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2. Infect Immun 68: 2231-2236.
32. Stephens HA, Brown AE, Chandanayingyong D, Webster HK, Sirikong M, et al. (1995) The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen. Eur J Immunol 25: 3142-3147.
33. Beck HP, Felger I, Barker M, Bugawan T, Genton B, et al. (1995) Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population. Am J Trop Med Hyg 53: 284-288.
34. Riley EM, Olerup O, Bennett S, Rowe P, Allen SJ, et al. (1992) MHC and malaria: the relationship between HLA class II alleles and immune responses to Plasmodium falciparum. Int Immunol 4: 1055-1063.
35. Patarroyo ME, Vinasco J, Amador R, Espejo F, Silva Y, et al. (1991) Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum. Parasite Immunol 13: 509-516.
36. Pratt-Riccio LR, Lima-Junior JC, Carvalho LJ, Theisen M, Espindola-Mendes EC, et al. (2005) Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria. Am J Trop Med Hyg 73: 1096-1103.
37. Oliveira-Ferreira J, Pratt-Riccio LR, Arruda M, Santos F, Ribeiro CT, et al. (2004) HLA class II and antibody responses to circumsporozoite protein repeats of P. vivax (VK210, VK247 and P. vivax-like) in individuals naturally exposed to malaria. Acta Trop 92: 63-69.
38. Banic DM, Goldberg AC, Pratt-Riccio LR, De Oliveira-Ferreira J, Santos F, et al. (2002) Human leukocyte antigen class II control of the immune response to p126-derived amino terminal peptide from Plasmodium falciparum. Am J Trop Med Hyg 66: 509-515.
39. SVS SdVeS-, (2011) Sistema de Informações Gerenciais e Divulgação- SIG-Malária. Ministério da Saúde.
40. McCutchan TF, Lal AA, de la Cruz VF, Miller LH, Maloy WL, et al. (1985) Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science 230: 1381-1383.
41. Pratt-Riccio LR, Sallenave-Sales S, de Oliveira-Ferreira J, da Silva BT, Guimaraes ML, et al. (2008) Evaluation of the genetic polymorphism of Plasmodium falciparum P126 protein (SERA or SERP) and its influence on naturally acquired specific antibody responses in malaria-infected individuals living in the Brazilian Amazon. Malar J 7: 144.
42. Bastos MS, da Silva-Nunes M, Malafronte RS, Hoffmann EH, Wunderlich G, et al. (2007) Antigenic polymorphism and naturally acquired antibodies to Plasmodium vivax merozoite surface protein 1 in rural Amazonians. Clin Vaccine Immunol 14: 1249-1259.
43. Cowan GJ, Creasey AM, Dhanasarnsombut K, Thomas AW, Remarque EJ, et al. (2011) A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. PLoS One 6: e26616.
44. Volpini WM, Testa GV, Marques SB, Alves LI, Silva ME, et al. (2001) Family-based association of HLA class II alleles and haplotypes with type I diabetes in Brazilians reveals some characteristics of a highly diversified population. Hum Immunol 62: 1226-1233.
45. Jepson A, Banya W, Sisay-Joof F, Hassan-King M, Nunes C, et al. (1997) Quantification of the relative contribution of major histocompatibility complex (MHC) and non-MHC genes to human immune responses to foreign antigens. Infect Immun 65: 872-876.
46. Zhang Q, Xue X, Xu X, Wang C, Chang W, et al. (2009) Influence of HLA-DRB1 alleles on antibody responses to PfCP-2.9-immunized and naturally infected individuals. J Clin Immunol 29: 454-460.
47. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR, (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39: D913-919.
48. Riley E, Olerup O, (1992) HLA polymorphisms and evolution. Immunol Today 13: 333-335.
49. Fowkes FJ, Richards JS, Simpson JA, Beeson JG, (2010) The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 7: e1000218.
50. Iriemenam NC, Khirelsied AH, Nasr A, ElGhazali G, Giha HA, et al. (2009) Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine 27: 62-71.
51. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76: 2240-2248.
52. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, et al. (1994) Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.
53. Buhler S, Sanchez-Mazas A, (2011) HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events. PLoS One 6: e14643.
54. Ribeiro RS, Ladeira L, Rezende AM, Fontes CJ, Carvalho LH, et al. (2011) Analysis of the genetic variability of PvMSP-3alpha among Plasmodium vivax in Brazilian field isolates. Mem Inst Oswaldo Cruz 106 (Suppl 1): 27-33.
55. Doolan DL, Dobano C, Baird JK, (2009) Acquired immunity to malaria. Clin Microbiol Rev 22 13-36, Table of Contents.
56. Dias S, Somarathna M, Manamperi A, Escalante AA, Gunasekera AM, et al. (2011) Evaluation of the genetic diversity of domain II of Plasmodium vivax Apical Membrane Antigen 1 (PvAMA-1) and the ensuing strain-specific immune responses in patients from Sri Lanka. Vaccine 29: 7491-7504.
57. Oliveira-Ferreira J, Lacerda MV, Brasil P, Ladislau JL, Tauil PL, et al. (2010) Malaria in Brazil: an overview. Malar J 9: 115.
58. Lima-Junior JC, Banic DM, Tran TM, Meyer VS, De-Simone SG, et al. (2010) Promiscuous T-cell epitopes of Plasmodium merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally exposed to malaria in the Brazilian Amazon. Vaccine 28: 3185-3191.
59. Cunha MG, Rodrigues MM, Soares IS, (2001) Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors. Vaccine 20: 385-396.